Register
Forgot your password?

Reconstruction of atrioventricular valves in patients with antiphospholipid syndrom

Authors: Skopin I.I., Kakhktsyan P.V., Latyshev M.S., Kopylova N.S., Khugaev G.A., Sokol’skaya N.O.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation

For correspondence:  Sign in or register.

Type:  Case reports


DOI: https://doi.org/10.24022/1997-3187-2021-15-1-108-117

For citation: Skopin I.I., Kakhktsyan P.V., Latyshev M.S., Kopylova N.S., Khugaev G.A., Sokol’skaya N.O. Reconstruction of atrioventricular valves in patients with antiphospholipid syndrome. Creative Cardiology. 2021; 15 (1): 108–17 (in Russ.). DOI: 10.24022/1997-3187-2021-15-1-108-117

Received / Accepted:  11.03.2021 / 17.03.2021

Keywords: antiphospholipid syndrome Libman–Sacks endocarditis mitral valve reconstruction of mitral valve systemic lupus erythematosus

Download
Full text:  

 

Abstract

In the mid-1980s, rheumatologist G.R. Hughes described an autoimmune state of hypercoagulation as a result of hyperproduction of antiphospholipid antibodies, which later became known as antiphospholipid syndrome or Hughes syndrome. The earliest clinical manifestation of Hughes syndrome is damage to the valvular complex of the heart, the frequency of which ranges from 33 to 76%. In most cases, mitral valve damage occurs, the severity of which varies from minimal changes (slight regurgitation or thickening of the valve cusps) to severe (hemodynamically significant stenosis and/or valve insufficiency). In the literature there is an extremely small number of publications devoted to the results of surgical treatment of patients with valve damage in the antiphospholipid syndrome. The article presents a case of successful mitral valve reconstruction in a patient with Libman–Sacks endocarditis caused by secondary antiphospholipid syndrome against systemic lupus erythematosus.

References

  1. Nasonov E.L., Salozhin K.V., Fomicheva O.A., Kliukvina N.G., Karpov I.A., Vilchinskaia M.I. et al. Anti-endothelial antibodies and defects of heart valves in antiphospholipid syndrome: analysis of pathogenic mechanisms. Clinical Medicine. 1997; 75 (2): 17–22 (in Russ.).
  2. Hughes G.R.V., Gharavi A.E., Harris A.E. The anticardiolipin syndrome. J. Rheum. 1986; 13: 486–9.
  3. Barbhaiya M., Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr. Rheumatol. Rep. 2011; 13: 59–69. DOI: 10.1007/s11926-010- 0149-3
  4. Karateev A.E., Nasonov E.L. Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs. Rheumatology Science and Practice. 2019; 57 (2): 197–209 (in Russ.). DOI: 10.14412/1995-4484-2019-197-209
  5. Vianna J.L., Khamashta M.A., Ordi-Ros J., Font J., Cervera R., Lopez-Soto A. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Amer. J. Med. 1994; 96: 3–9. DOI: 10.1016/0002-9343(94)90108-2
  6. Asherson R.A., Tikly M., Staub H., Wilmshurst P.T., Coltart D.J., Khamashta M. et al. Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies. Ann. Rheum. Dis. 1990; 49: 107–8. DOI: 10.1136/ard.49.2.107
  7. Cervera R., Tektonidou M.G., Espinosa G., Cabral A.R., González E.B., Erkan D. et al. Task force on catastrophic antiphospholipid syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011; 20: 165–73. DOI: 10.1177/0961203310395051
  8. Tenedios F., Erkan D., Lockshin M.D. Cardiac manifestations in the antiphospholipid syndrome. Rheum. Dis. Clin. North. Am. 2006; 32: 491–507. DOI: 10.1016/j.rdc.2006.05.008
  9. Petri M.A. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J. Rheumatol. 2004; 31: 2329–30.
  10. Gorki H., Malinovski V., Stanbridge R.D.L. The antiphospholipid syndrome and heart valve surgery. Eur. J. Cardiothorac. Surg. 2008; 33: 168–81. DOI: 10.1016/j.ejcts.2007.11.004
  11. Erdozain J.G., Ruiz-Irastorza G., Segura M.I., Amigo M.C., Espinosa G., Pomar J.L. et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res. 2012; 14: 1256–60. DOI: 10.1002/acr.21670
  12. Berkun Y., Elami A., Meir K., Mevorach D., Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J. Thorac. Cardiovasc. Surg. 2004; 127: 414–20. DOI: 10.1016/j.jtcvs.2003.07.016
  13. Espínola-Zavaleta N., Vargas-Barrón J., Colmenares-Galvis T., Cruz-Cruz F., Romero-Cárdenas A., Keirns C. et al. Echocardiagraphic evalution of patients with primary antiphospholipid syndrome. Am. Heart. J. 1999; 137: 973–9. DOI: 10.1016/s0002-8703(99)70424-2
  14. Myers G.J., Hirsch G.M. Double valve replacement in a patients with anticardiolipin antibody syndrome. Perfusion. 1999; 14: 397–401. DOI: 10.1177/026765919901400512
  15. Brownstein L., Bartholomew T.P., Silver D.G., Berry C.M. A case report of mitral valve replacement in patients with lupus antibody syndrome. Perfusion. 2003; 18: 373–6. DOI: 10.1191/0267659103pf689oa

About Authors

  • Ivan I. Skopin, Dr. Med. Sc., Professor, Head of Department of the Heart Valves and Coronary Arteries Reconstructive Surgery, Director of Institute of Coronary and Vascular Surgery, ORCID
  • Pavel V. Kakhktsyan, Cand. Med. Sc., Senior Researcher, ORCID
  • Mikhail S. Latyshev, Cand. Med. Sc., Junior Researcher, ORCID
  • Natal’ya S. Kopylova, Cand. Med. Sc., Senior Researcher, ORCID
  • Georgiy A. Khugaev, Junior Researcher, ORCID
  • Nadezhda O. Sokol’skaya, Dr. Med. Sc., Scientific Secretary, Head of Group of Ultrasound and Functional Diagnostics, ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by